Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2985 L-161240
Potent inhibitor of LpxC and lipid A biosynthesis
More description
DCC2984 Kys05047
Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells
More description
DCC2983 Kya1797
Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres
More description
DCC2982 Ky1022
Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer
More description
DCC2981 Kva-d-88
Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo
More description
DCC2980 Kv2.1/syntaxin-in-cpd5
Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction
More description
DCC2979 kv1.5-in-iiii
Potent Kv1.5 inhibitor
More description
DCC2978 Kurasoin B
Novel protein farnesyltransferase inhibitor
More description
DCC2977 Kunb31
Novel potent and selective inhibitor of Hsp90β
More description
DCC2976 Kufal194
Novel selective DYRK1A inhibitor
More description
DCC2975 Ku-2285
Hypoxic cell radiosensitizer
More description
DCC2974 Kta-439
Thyroid hormone receptor β (TRβ) selective agonist
More description
DCC2973 Kt2-962
TXA2/prostaglandin endoperoxide receptor antagonist
More description
DCC2972 Kt-182
Potent and selective inhibitor of ABHD6
More description
DCC2971 Kspa-1
Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP
More description
DCC2970 Ksl-128114
Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma
More description
DCC2969 Ksk120
Novel inhibitor of transcriptional activity in Chlamydia trachomatis
More description
DCC2968 kscm-5
Ligand of the sigma receptor
More description
DCC2967 Kscm-11
Ligand of the sigma receptor
More description
DCC2966 kscm-1
Selective ligand of the sigma-1 receptor
More description
DCC2965 Ksc-392-150
Novel inhibitor of the permeability transition pore (PTP)
More description
DCC2964 Ks-133
Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders
More description
DCC2963 Krp-204
Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity
More description
DCC2962 Krp-199
Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo
More description
DCC2961 Krp-109
Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes
More description
DCC2960 Krn-8602 Hydrochloride
Topo II inhibitor, exhibiting cytotoxic effects against tumour cells
More description
DCC2959 Krn4884
Potassium channel opener
More description
DCC2958 Krm-ii-08
Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c
More description
DCC2957 Krc-327
Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.
More description
DCC2956 Krc-108
Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X